Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alnylam Sheds Legal Trouble But Picks Up Manufacturing Challenge In Tekmira Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

Alnylam is paying Tekmira $65 million to resolve an RNAi trade secrets suit; the new licensing pact reduces Alnylam’s future milestone and royalty payments on three compounds and allows the firm to manufacture its own drug candidates.


Related Content

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn
Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates
The Alnylam Turnaround: What Changed Investors’ Minds?
RNAi Creates Novel Court Filings; Tekmira In Trade Secrets Dispute With AlCana
From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts